In addition, in vivo studies in a mouse model of PE demonstrate that CALCA treatment protects from the development of sFLT-1-induced PE-like symptoms such as hypertension, ATII hypersensitivity, the elevated albumin–creatinine ratio, and fetal growth restriction. Here, ALB is linked to hypertensive disorder.